Trump Tariff Alert: EU and Japan Will Be Exempted From US President Donald Trump’s 100% Pharma Tariffs

President Donald Trump has introduced new tariffs on pharmaceutical imports, but countries with existing trade agreements with the U.S. will be exempt. A White House official confirmed that the European Union and Japan are among those spared. The EU's pharmaceutical duties will not exceed 15%, while Japan's rates will align with their current agreement.

On Thursday, Trump declared a 100% tariff on branded or patented pharmaceuticals unless companies are constructing manufacturing plants in the U.S. This means no tariffs if construction is underway. The announcement raised concerns internationally about the status of existing agreements.

Tariff Exemptions for New U.S. Facilities

The White House clarified that companies planning to build facilities in the U.S. could also be exempt from these tariffs. The Commerce Department will review and approve such projects to determine eligibility for exemptions.

A joint statement from the U.S. and Japan specified that tariffs on Japanese drugs and semiconductors would not surpass those applied to other partners, including the EU. This ensures consistency in tariff application across different trade partners.

Recent Moves to Enforce Trade Agreements

In recent days, the administration has taken steps to uphold its trade commitments with the EU. Earlier this week, auto tariffs were reduced from 25% to 15%, aligning with existing agreements.

The sudden tariff announcement has prompted questions from foreign governments regarding the applicability of current agreements. However, assurances have been given that these agreements remain valid under the new tariff structure.

This development highlights ongoing efforts by the U.S. administration to encourage domestic pharmaceutical manufacturing while maintaining international trade relationships through existing agreements.